110 related articles for article (PubMed ID: 21501692)
21. Ciclesonide nasal spray: in allergic rhinitis.
Dhillon S; Wagstaff AJ
Drugs; 2008; 68(6):875-83. PubMed ID: 18416590
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic disposition of inhaled ciclesonide and its metabolite desisobutyryl-ciclesonide in healthy subjects and patients with asthma are similar.
Nave R; Gunawardena KA; Zech K; Bethke TD
Int J Clin Pharmacol Ther; 2006 Jan; 44(1):1-7. PubMed ID: 16425964
[TBL] [Abstract][Full Text] [Related]
23. No hypothalamic-pituitary-adrenal function effect with beclomethasone dipropionate nasal aerosol, based on 24-hour serum cortisol in pediatric allergic rhinitis.
Hampel FC; Nayak NA; Segall N; Small CJ; Li J; Tantry SK
Ann Allergy Asthma Immunol; 2015 Aug; 115(2):137-42. PubMed ID: 26250771
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of ciclesonide hydrofluoroalkane nasal aerosol once daily for the treatment of seasonal allergic rhinitis.
LaForce C; van Bavel J; Meltzer EO; Wingertzahn MA
Ann Allergy Asthma Immunol; 2009 Aug; 103(2):166-73. PubMed ID: 19739431
[TBL] [Abstract][Full Text] [Related]
25. Effects of ciclesonide and fluticasone on cortisol secretion in patients with persistent asthma.
Derom E; Louis R; Tiesler C; Engelstätter R; Kaufman JM; Joos GF
Eur Respir J; 2009 Jun; 33(6):1277-86. PubMed ID: 19164356
[TBL] [Abstract][Full Text] [Related]
26. In vitro activation of the corticosteroid ciclesonide in animal nasal mucosal homogenates.
Sato H; Nave R; Nonaka T; Mochizuki T; Takahama S; Kondo S
Biopharm Drug Dispos; 2007 Mar; 28(2):59-64. PubMed ID: 17163410
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of ciclesonide, 200 microg once daily, for the treatment of perennial allergic rhinitis.
Meltzer EO; Kunjibettu S; Hall N; Wingertzahn MA; Murcia C; Berger W; LaForce C
Ann Allergy Asthma Immunol; 2007 Feb; 98(2):175-81. PubMed ID: 17304887
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma.
Richter K; Kanniess F; Biberger C; Nave R; Magnussen H
J Clin Pharmacol; 2005 Feb; 45(2):146-52. PubMed ID: 15647406
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of [14C]ciclesonide after oral and intravenous administration to healthy subjects.
Nave R; Bethke TD; van Marle SP; Zech K
Clin Pharmacokinet; 2004; 43(7):479-86. PubMed ID: 15139796
[TBL] [Abstract][Full Text] [Related]
30. Model-based covariate pharmacokinetic analysis and lack of cortisol suppression by the new inhaled corticosteroid ciclesonide using a novel cortisol release model.
Rohatagi S; Krishnaswami S; Pfister M; Sahasranaman S
Am J Ther; 2005; 12(5):385-97. PubMed ID: 16148423
[TBL] [Abstract][Full Text] [Related]
31. Lack of pharmacokinetic drug-drug interaction between ciclesonide and erythromycin.
Nave R; Drollmann A; Steinijans VW; Zech K; Bethke TD
Int J Clin Pharmacol Ther; 2005 Jun; 43(6):264-70. PubMed ID: 15968883
[TBL] [Abstract][Full Text] [Related]
32. In vitro metabolism of ciclesonide in human nasal epithelial cells.
Sato H; Nave R; Nonaka T; Mochizuki T; Takahama S; Kondo S
Biopharm Drug Dispos; 2007 Jan; 28(1):43-50. PubMed ID: 17117454
[TBL] [Abstract][Full Text] [Related]
33. Once-daily treatment with beclomethasone dipropionate nasal aerosol does not affect hypothalamic-pituitary-adrenal axis function.
Ratner PH; Miller SD; Hampel FC; Melchior A; Dunbar SA; Tantry SK
Ann Allergy Asthma Immunol; 2012 Nov; 109(5):336-41. PubMed ID: 23062389
[TBL] [Abstract][Full Text] [Related]
34. Absolute bioavailability of intranasal fluticasone furoate in healthy subjects.
Allen A; Down G; Newland A; Reynard K; Rousell V; Salmon E; Scott R
Clin Ther; 2007 Jul; 29(7):1415-20. PubMed ID: 17825692
[TBL] [Abstract][Full Text] [Related]
35. Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects.
Nave R; Zech K; Bethke TD
Eur J Clin Pharmacol; 2005 May; 61(3):203-8. PubMed ID: 15824911
[TBL] [Abstract][Full Text] [Related]
36. High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma.
Newman S; Salmon A; Nave R; Drollmann A
Respir Med; 2006 Mar; 100(3):375-84. PubMed ID: 16275052
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis.
Sastre J; Mullol J; Valero A; Valiente R;
Curr Med Res Opin; 2012 Jan; 28(1):121-30. PubMed ID: 22077106
[TBL] [Abstract][Full Text] [Related]
38. Intranasal ciclesonide coadministration with inhaled fluticasone propionate-salmeterol does not suppress cortisol in allergic rhinitis patients.
Kim K; Quesada J; Szmaydy-Rikken N; Darken P; Shah T
J Asthma; 2007 Sep; 44(7):515-20. PubMed ID: 17885853
[TBL] [Abstract][Full Text] [Related]
39. Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide.
Nave R; Meyer W; Fuhst R; Zech K
Pulm Pharmacol Ther; 2005; 18(6):390-6. PubMed ID: 16179214
[TBL] [Abstract][Full Text] [Related]
40. Safety and clinical relief over 1 year with triamcinolone acetonide hydrofluoroalkane-134a nasal aerosol in patients with perennial allergic rhinitis.
Weber R; Garcia J; Faruqi R; Banerji D; Georges G;
Allergy Asthma Proc; 2006; 27(3):243-7. PubMed ID: 16913268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
